Tauriga Sciences Inc. Commences Development of Vegan, CBD Infused Pet Treat
December 11 2020 - 10:00AM
InvestorsHub NewsWire
NEW YORK, NY -- December 11, 2020 -- InvestorsHub
NewsWire -- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today announced that it has
commenced the development of a Vegan, Cannabidiol (“CBD”) infused
Pet Food Treat (“Pet Treat”). The Company has contracted
an industry expert to help with: formulations, specifications,
designs, regulations, and certifications. The Company’s
aim is to commercially launch its proposed Pet Treat product,
during March
2021.
Recall that on June 8, 2020, the Company issued the
press release: “Tauriga Sciences Inc. Taking Concrete Steps to
Expand into the Fast-Growing CBD Infused Pet Food Market
Segment.” For the Year 2020, the U.S. pet treat market
is projected at $7 Billion – driven by CBD & Other Ingredient
trends.
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) &
(Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear
Bellini). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce
website: www.taurigum.com).
Please visit our corporate website, for additional information, as
well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, are
its two ongoing biotechnology initiatives. The first one
relates to the development of a Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed to help
patients that are subjected to ongoing chemotherapy
treatment). On March 18, 2020, the Company announced that it
filed a provisional U.S. patent application covering its
pharmaceutical grade version of Tauri-Gum™. The Patent,
filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS,
METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The
second one relates to a collaboration agreement with Aegea
Biotechnologies Inc. for the co-development of a rapid,
multiplexed, Novel Coronavirus (COVID-19) test with superior
sensitivity and
selectivity.
On October 6, 2020, the Company announced that it
has been approved to operate as a U.S. Government Vendor (CAGE CODE
# 8QXV4)
On October 7, 2020 the Company disclosed a
Strategic Alliance with Think BIG, LLC, Social Impact Startup
Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.”
Wallace.
The Company is headquartered in New York City and
operates a regional office in Barcelona, Spain. In
addition, the Company operates a full time E-Commerce fulfillment
center located in LaGrangeville, New
York.
DISCLAIMER -- Forward-Looking
Statements
This press release contains certain
“forward-looking statements” as defined by the Private Securities
Litigation Reform Act of 1995 which represent management’s beliefs
and assumptions concerning future events. These forward-looking
statements are often indicated by using words such as “may,”
“will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as
well as the attainment of certain corporate goals and milestones.
Forward-looking statements are based on present circumstances and
on management’s present beliefs with respect to events that have
not occurred, that may not occur, or that may occur with different
consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed
in forward looking statements due to known and unknown
risks and uncertainties, such as are not guarantees of general
economic and business conditions, the ability to successfully
develop and market products, consumer and business consumption
habits, the ability to consummate successful acquisition and
licensing transactions, fluctuations in exchange rates, and other
factors over which Tauriga has little or no control. Many of these
risks and uncertainties are discussed in greater detail in the
“Risk Factors” section of Tauriga’s Form 10-K and other filings
made from time to time with the Securities and Exchange Commission.
Such forward-looking statements are made only as of the date of
this release, and Tauriga assumes no obligation to update
forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these
forward-looking
statements.
Contact:
Tauriga Sciences,
Inc.
555 Madison Avenue, 5th
Floor
New York,
NY 10022
Chief Executive
Officer
Mr. Seth M.
Shaw
Email: sshaw@tauriga.com
cell # (917) 796
9926
Instagram:
@taurigum
Twitter:
@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024